• Corpus ID: 74287752

ECONOMICS OF MULTIPLE SCLEROSIS AND ITS TREATMENT

@inproceedings{Bainbridge2007ECONOMICSOM,
  title={ECONOMICS OF MULTIPLE SCLEROSIS AND ITS TREATMENT},
  author={Jacquelyn L. Bainbridge},
  year={2007}
}
Multiple sclerosis (MS) is a chronic, severely disabling disease that typically makes its first appearance during young adulthood or early middle age. The lifetime treatment costs of MS exceed the costs of other disabling neurologic conditions, such as stroke or Alzheimer’s disease. Patients with MS have healthcare expenses that far exceed the expenses of typical patients with health insurance, with some studies suggesting average annual direct treatment costs exceeding $20 000 per patient… 
A Study on the Direct and Indirect Costs of Multiple Sclerosis Based on Expanded Disability Status Scale Score in Khuzestan, Iran
TLDR
Cost mean per MS patients was relatively high and results showed that cost of disease had positive and significant relationships with EDSS score that is, progression of disability increase costs of patients.
S100B targeting to reduce demyelination and EAE pathogenesis

References

SHOWING 1-10 OF 13 REFERENCES
Cost of managing an episode of relapse in multiple sclerosis in the United States
TLDR
Management strategies leading to a reduction in the frequency and severity of a relapse, less reliance on inpatient care, or increased access to steroid infusions in the home, would have a substantial impact on the economic consequences of managing relapses.
Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database.
TLDR
A comparison of 2004 costs with 1995 costs demonstrated that total annual MS-related treatment costs increased by 35%, from $9,515 in 1995 to $12,879 in 2004, and costs did differ among age categories and by insurance type and payer.
Stepped-care approach to treating MS: a managed care treatment algorithm.
TLDR
Stepped care, as outlined in this model treatment algorithm for the managed care setting, is an effective method to achieve the fundamental goal of MS treatment, that is, to delay disease progression and the associated disability and cognitive impairment.
A comprehensive assessment of the cost of multiple sclerosis in the United States
TLDR
A survey of persons with MS who were members of the National Multiple Sclerosis Society to obtain data on their cost of personal health services, other services, equipment, and earnings, and compensation of such cost in the form of health insurance, income support, and other subsidies was measured.
The costs and consequences of multiple sclerosis relapses: A managed care perspective
  • T. Morrow
  • Medicine, Psychology
    Journal of the Neurological Sciences
  • 2007
Access to health care for people with multiple sclerosis
TLDR
Key indicators of access to health care were examined and found that the majority of participants had health insurance, a usual source of care, and access to specialty care, while out-of-pocket health care expenditures were twice those found for the general population.
Cost of multiple sclerosis by level of disability: a review of literature
TLDR
Rise in cost is positively correlated to scores on the EDSS categories, and therefore agents with a capacity to prevent or arrest the rate of MS progression may affect the overall cost of MS.
Recombinant therapeutics: from bench to bedside (if your health plan concurs).
TLDR
A talented medical student at the authors' institution was recently diagnosed with multiple sclerosis; however, her annual cap from student health insurance coverage for outpatient drug expenses is only Dollars 3000, a sum that would be exceeded within 3 months and leave her without coverage for symptomatic medications also required for her care.
Benefit design and specialty drug use.
TLDR
Examination of spending by privately insured patients with four conditions often treated with specialty drugs finds that specialty drug use is largely insensitive to cost sharing, with price elasticities ranging from 0.01 to 0.21.
...
...